In this explorative study on a small cohort of SMA type 3 patients, we report our preliminary findings on the effects of Nusinersen administration on motor function over the short‐term and describe changes over time in the CSF concentration of both pNfH and NfL, which were assessed as potential biomarkers of treatment response. The gene discussed is NEFL; the disease is spinal muscular atrophy, type III.